Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

MRC Technology and CAS Collaborate to Identify New Targets for Drug Discovery

Published: Friday, November 30, 2012
Last Updated: Friday, November 30, 2012
Bookmark and Share
Initiative brings together global expertise to streamline drug discovery.

MRC Technology has announced that it has entered into a strategic drug discovery collaboration with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Science (CAS).

The agreement will combine the SIBCB’s research expertise in generating potential new drug targets, with MRC Technology’s experience in further developing early stage research for pharmaceutical application and commercialization.

The focus of the collaboration is to fast track innovative drugable targets to create potent and selective novel therapeutics.

The collaboration was formalized at a signing ceremony held in Shanghai and attended by the senior team from both organizations including Dave Tapolczay and Michael Dalrymple (CEO and Director of Business Development, MRC Technology) and Professors Naihe Jing, Zhengjun Chen and Ge Jiang (Executive Director, Assistant Director and Head of Science and Technology respectively, SIBCB).

Dave Tapolczay, MRC Techology’s CEO commented, “SIBCB is one of the world’s leading academic research institutions and the initiative reflects our joint commitment to delivering drugs for the treatment of diseases of global significance. The collaboration gives us a strong partner in China and access to potential new targets to further develop into drug therapies.”

Supporting technology transfer and IP management efforts, MRC Technology set up its drug discovery laboratories in order to bridge the gap between innovative, early stage academic research and the development of intellectual property suitable for licensing to industry for further development and commercialization.

De-risking novel targets by providing proof of concept and pharma-quality data packages fulfils a clear need in the drug discovery process.

The collaboration opens the MRC Technology laboratories up to a new source of targets from SIBCB researchers.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Charity Seeks Diagnostic Partners to Deliver New Patient Treatments
Call for Diagnostics from MRCT for scientists with promising results lead to new tests.
Thursday, October 29, 2015
MRC Technology Appoints Technology Transfer Director
Appointment of Andrew Farquharson as Director from 1 September.
Wednesday, July 08, 2015
MRC Technology, Peptinnovate Collaborate
This partnership has been formed to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
Wednesday, June 10, 2015
MRC Technology and NYU School of Medicine Collaborate
Collaboration will develop develop biologics for inflammatory bone disease.
Thursday, April 23, 2015
MRC Technology Appoints Finance Director
MRC Technology, an independent life science medical research charity, has appointed Andrew Mercieca as its Finance Director from 1 April 2015. Andrew joined the company as Interim Finance Director in August 2014.
Friday, April 17, 2015
MRC Technology Negotiates Licence Deal with Quantifoil Micro Tools GmbH for Ultrastable Gold Support (UltrAuFoil) Technology
The gold supports enable the determination of currently intractable protein structures by electron cryomicroscopy.
Tuesday, March 31, 2015
First Treatment Approved Under EAMS
New immunotherapy (pembrolizumab) made available in the UK for treatment of adults with advanced melanoma.
Friday, March 13, 2015
First Treatment Approved under EAMS Developed Using Antibody Humanization Expertise at UK’s MRC Technology
New breakthrough immunotherapy (pembrolizumab) launched in the UK for treatment of adults with advanced melanoma.
Wednesday, March 11, 2015
MRC Technology Launches Respiratory ‘Call for Targets’
Project focused on potential small molecule or antibody targets in pathways important in the development or progression of respiratory disease.
Monday, March 02, 2015
MRC Technology Appoints General Counsel and Company Secretary
Dr Edward Bliss will join MRCT on 16 March.
Wednesday, February 04, 2015
MRC Technology and Yabao Pharmaceuticals Announce Exclusive Partnership
Partnership in China to develop novel therapeutics for Parkinson’s disease.
Friday, November 28, 2014
Charities Pledge to Inject Millions to Jump Start Drug Development for Brain Diseases
MRC Technology to lead Neurodegeneration Medicines Acceleration Programme to uncover promising drugs in pharma libraries.
Tuesday, November 18, 2014
MRC Technology and Proximagen Collaborate
Project will investigate a small molecule solution for Macrophage migration inhibitory factor.
Monday, October 13, 2014
Dr. John Stageman Appointed Chair of the Board for MRC Technology
Dr. Stageman has a wealth of experience in the pharmaceutical industry and biotechnology research.
Wednesday, October 01, 2014
Breakthrough Melanoma Treatment, Keytruda, Developed
New immunotherapy launched in the US for treatment of adults with advanced melanoma, developed using antibody humanization expertise at UK’s MRC Technology.
Friday, September 05, 2014
Scientific News
Microdroplet Reactors Mimic Living Systems
Researchers use microdroplets to study non-equilibrium reactions like those in living organisms.
NIH Researchers Identify Striking Genomic Signature for Cancer
Institute has identified striking signature shared by five types of cancer.
CRI Develops Innovative Approach for Identifying Lung Cancer
Institute has developed innovative approach for identifying processes that fuel tumor growth in lung cancer patients.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
What do Banana Peels and Human Skin Have in Common?
Human skin and banana peels have something in common: they produce the same enzyme when attacked. By studying fruit, researchers have come up with an accurate method for diagnosing the stages of this form of skin cancer.
The Spice of Life
Scientists discover important genetic source of human diversity.
Cytoskeleton Crew
Findings confirm sugar's role in helping cancers survive by changing cellular architecture.
The Power of Three
Overlooked portion of cell “death receptor” critical in some cancers, autoimmune diseases.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Removing Race from Human Genetic Research
A group of scientists are urging their colleagues to take a step forward and stop using racial categories when researching and studying human genetics.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!